Sildenafil

These are the frequent and mild ones, gathered over about twelve weeks. The rare and serious events the label warns about, an erection lasting beyond four hours among them, are too uncommon for trials this size to count, so their absence here is not evidence of their absence.

The two figures come from separate trials rather than one comparison, so the size of the gap is indicative rather than measured. Men in the diabetes trial had lived with it twelve years on average, and response is not broken down by how much nerve or vessel damage they had.

Enrolled men skewed towards mild and moderate erectile dysfunction, so these figures sit at the optimistic end of what an unselected clinic sees. Success was recorded by the men themselves, in diaries. Most trials ran about twelve weeks, and almost all were funded by the manufacturer.

Six minutes of walking stands in for exercise capacity, not for living longer: the trial ran twelve weeks, was not powered for mortality, and found no significant difference in clinical worsening. It also enrolled only certain causes of raised lung pressure.

This covers only men who had both nerve bundles spared. Where the nerves were not spared, recovery is substantially worse and these trials say nothing about it. Eight trials, several industry-funded, with dosing and timing after surgery differing between them.

The rule is written from blood-pressure measurements, not from counted faints or falls. How much it matters may depend on how long a man has already been on his alpha-blocker, and the review reporting that describes it as suggested rather than settled.

This is a dosing rule read off a label, not a measured harm rate: the label sets the ceiling without publishing what happened to anyone who exceeded it. The three drugs named are examples of a wider group that blocks the same enzyme.

Neither body of evidence included a no-drug arm, so this says which schedule to pick and not whether either beats nothing. The prostatectomy trial took men who were fully potent beforehand and kept both nerve bundles, the group likeliest to recover anyway. A null in 100 men is not equivalence.

A prescribing label sets rules without publishing the data behind them. The starting dose is lower than 50mg for several groups, including anyone already taking a drug that slows sildenafil's clearance.

Thirty-one men in total across two crossover trials, all with stable angina, so the exact size of the fall need not transfer to anyone else. Blood pressure was what these trials counted, not faints, heart attacks or deaths, and a trial counting those in people on nitrates will never be run.

Only 25mg was tested, the lowest marketed strength of sildenafil, so this does not say what 50 or 100mg would do in the same men. Sixty men answering yes or no at home can show the absence of a large effect, not of a small one. The recovery-time result rests on twelve men against four.

A prescribing label sets doses and rules without publishing the data behind them, and its wording is negotiated between a manufacturer and a regulator. Both of these are the US labels, and neither describes what doctors do outside them.

The ranking comes from indirect comparison across trials that never tested these doses against each other, which is far less stable than head-to-head data. Read as advice for one man choosing a dose, it means nothing. Most of the trials underneath it were short and manufacturer-funded.

Every study on both sides is observational, so men who take these drugs differ from men who do not in ways no adjustment removes, sun exposure among them. They also see doctors more often, which alone yields more diagnoses of a cancer found by looking. The newer pooling's studies barely agree.

Men on erectile-dysfunction drugs are diagnosed with melanoma more often. What that means is unsettled: one analysis reads it as shared sun exposure, and a later one urges at-risk men to avoid the drugs without answering that argument.

Recent use carried a higher hazard ratio than current use, 1.60 against 1.25, which points at something other than the drug. The lower edge of the confidence interval sits at 1.01. Exposure was inferred from pharmacy fills, and the finding covers the whole drug class rather than sildenafil alone.

Five observational studies, no randomised evidence, and the risk ratios are not adjusted for the vascular disease that causes both erectile difficulty and this kind of vision loss. The subgroup figures rest on very few cases, because the condition is rare and hard to diagnose in the first place.

Pooled studies found no clear rise in sudden optic-nerve damage for the drug class, yet sildenafil alone came out at about twice the risk. Which holds is open, against a base rate of 2.5 to 11.8 cases per 100,000 men over 50 a year.

The review is narrative rather than systematic, written by a single author with long-standing industry ties in this field and published in a journal supplement. A label naming no interval is not evidence that no interval is safe; it is a regulator declining to guess.

How long after sildenafil a nitrate becomes safe has no agreed answer. One review finds the interaction gone by 24 hours; the US regulator, with the same interaction studies in hand, declines to name any interval.

This was an extension study, not the randomised trial: children carried their original dose assignment forward while former placebo recipients were newly randomised, so the groups did not start alike. Those who died were far likelier to have the severe inherited forms and worse baseline function.

In a long-term follow-up, children on the highest sildenafil dose died at nearly four times the lowest-dose rate. Whether dose caused it is open: the groups did not start alike, and the sickest children were over-represented among deaths.

The arrow could point either way and this design cannot separate them: recreational use may erode confidence, or men who already have difficulty may reach for the drug and call it recreational. The data are from 2006 and 2007, before telehealth prescribing changed how young men get these drugs.